Bausch & Lomb UK adrenaline auto-injector alert issued for UK patients

A drug alert has been issued from an affiliate of Bausch & Lomb UK after Pharmaswiss Česka republika said there was a risk of its Emerade product failing to deliver a dose of adrenaline from the syringe due to a blockage in the needle.

The alert is said to affect three products; the Emerade 150 micrograms solutions, 300 micrograms solution and 500 micrograms solution for injection in pre-filled syringe.

The problem was first detected in June 2018 with potential to affect 1.5 in every 10,000 pens, but the potential occurrence of needle blockage has risen to 2.3 in every 1,000 pens.

The Medicines and Healthcare products Regulatory Agency (MHRA) is not recalling batches of Emerade.

The manufacturer conducted extensive investigations and has implemented corrective actions. Emerade manufactured with all the corrective processes is expected to be introduced into the market from mid-July 2019.

Healthcare professionals have been advised to contact all patients and carers who have been issued with the device to inform them of the potential defect.